Detalhe da pesquisa
1.
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
Rheumatology (Oxford)
; 63(1): 140-148, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140539
2.
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Allergy
; 79(5): 1258-1270, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38108208
3.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet
; 396(10246): 255-266, 2020 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711801
4.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28629665
5.
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
J Am Acad Dermatol
; 77(1): 79-87.e1, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28396102
6.
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
J Allergy Clin Immunol
; 137(4): 1079-1090, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27059729
7.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
J Am Acad Dermatol
; 75(6): 1162-1170.e3, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692733
8.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
J Am Acad Dermatol
; 74(5): 841-50, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899199
9.
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
J Drugs Dermatol
; 15(5): 568-80, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27168266
10.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 47(3): 419-429, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35226304
11.
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
RMD Open
; 8(1)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577477
12.
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Arthritis Care Res (Hoboken)
; 72(3): 353-359, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207152
13.
Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.
J Clin Lipidol
; 11(5): 1243-1256, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751001